IL13 and neoplasm: TH2-like NKT cell subsets further inhibit the activation of tumor-specific T cells via secretion of IL-13 (49, 158, 159), while Tregs inhibit tumor-specific T cells via cell–cell interactions and secretion of IL-10 and TGF-β (243, 244).